NEWS & EVENTS
Relevant News
University of Montana disease treatment research center pulls in $22 million in grants
Original Article by https://missoulian.com/users/profile/KeilaSzpaller October, 9, 2018 A research center at the University of Montana earned $22.4 million this summer and fall...
Inimmune Receives $1M SBIR Phase II Grant
Montana biotech company receives Small Business Innovation Research Grant to develop novel treatments against infectious diseases. Inimmune Corporation, a biotechnology company located in Missoula,...
Missoula’s Inimmune receives $600K to develop novel treatments for seasonal allergies
Missoula-based Inimmune Corp. has received a nearly $600,000 federal grant to identify and advance novel treatments for seasonal allergies. In an announcement Wednesday, the biotechnology firm...
Inimmune named one of the top 8 Montana startups to watch
Originally written by DAVID ERICKSON (david.erickson@missoulian.com) and reported in the Missoulian. Three Missoula companies and two others in western Montana have made the Montana High...
Montana company receives funds for cutting edge infectious disease research and novel immunotherapeutic treatments
Inimmune Corporation, a startup biotechnology company located in Missoula Montana, recently received a Phase I Small Business Innovation Research (SBIR) award in the amount of $176,000 from the...
Inimmune lands Montana Department of Commerce Grant to Fund Technology Innovation
Montana Department of Commerce Director Pam Haxby-Cote today announced $862,000 in grants to nine research projects in five communities to encourage innovation, research and high-wage job creation.
Laid Off Employees Land Gigs at Newly Formed Biotech Inimmune
Eighteen months after GlaxoSmithKline (GSK) shuttered its vaccine research and development facility in Hamilton, Mont. and laid off about two dozen people, some of those jobs have returned to The Treasure State thanks to a new biotech startup partnered with the University of Montana
New Biotech Company Formed at UM’s MonTEC
Officials from a new biotech company, Inimmune Corporation, met with Gov. Steve Bullock
Upcoming Events
Upcoming Events
Look for us at these upcoming conferences. If you are interested in scheduling a face to face meeting during one of these conferences please use the contact button
BIO International – June 2020
Relevant Publications
Smith AJ, Li Y, Bazin-Lee H, St-Jean JR, Larocque D, Baldridge J. Evaluation of novel synthetic TLR7/8 agonists as human vaccine adjuvants. Vaccine. 2016. [Epub ahead of print].
Oberoi, H.; Yorgensen, Y.; Evans, J.; Burkhart, D.; PEG modified liposomes in combination with methylglycol chitosan enhances the murine sublingual immune response to influenza vaccination Journal of Controlled Release, Vol 223, 10 Feb 2016.
Spinner, J.; Oberoi, H.; Yorgensen, Y.; Burkhart, D.; Evans, J.; Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually Vaccine, Volume 33, pages5845-5853, 2015.
Khalaf, W. S. Bowen, H.G. Bazin , K.T. Ryter, M.T. Livesay, J.R. Ward, J.T. Evans, D.A. Johnson, “Characterization of TRIF selectivity in the AGP class of lipid A mimetics: Role of secondary lipid chains”, Bioorg. Med. Chem. Lett., 25, 547-533, 2015
H.G. Bazin, Y. Li, J.K. Khalaf , S. Mwakwari, M.T. Livesay, J.T. Evans, D.A. Johnson, “Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives”, Bioorg. Med. Chem. Lett., 25, 1318-1323, 2015
H.G. Bazin, L.S. Bess, M.T. Livesay, D.A. Johnson, “Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method”, Tetrahedron Lett, 57, 2063-2066, 2016
Mwakwari, L.S. Bess, H.G. Bazin, D.A. Johnson, “Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline”, Tetrahedron Lett, 57, 2093-2096, 2016